Companies in #Inflammatory lung disease

Celea Therapeutics is a clinical-stage respiratory therapeutics company spun out of PureTech Health in August 2025. Lead program is deupirfenidone (LYT-100), a Phase 3-ready deuterated pirfenidone candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic and inflammatory lung conditions.